Blood Clotting and Sickle Cell Disease Severity Study
Studies blood clotting in people with sickle cell disease who have severe hemolysis.
Plain-language title generated from the registry record
Registry title: Relationship Between Biological Phenotype, Clinical Severity of Sickle Cell Disease, and Blood Coagulation
Key facts
- Where
- Lyon, FranceSee the 2 sites
Where in France
- Insitut Hématologique et Oncologique Pédiatrique (IHOPe)Lyon, FranceNo longer taking part
- Service de Médecine Interne - Hôpital Edouard HerriotLyon, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT06619093
- Record updated
- 15 January 2025
- Original description
Sickle cell disease is characterized by chronic hemolytic anemia and blood rheological alterations. In addition, blood coagulation abnormalities have been reported in patients with sickle cell disease and hemolysis-derived products could be involved. The investigators hypothesized that patients with sickle cell disease and severe hemolysis (Lactate Dehydrogenase level \> 484 IU/L) could have an increased risk of hypercoagulable state and subsequent thromboembolic complications.Read full original descriptionShow less
Relationship Between Biological Phenotype, Clinical Severity of Sickle Cell Disease, and Blood Coagulation
Sickle cell disease is characterized by chronic hemolytic anemia and blood rheological alterations. In addition, blood coagulation abnormalities have been reported in patients with sickle cell disease and hemolysis-derived products could be involved. The investigators hypothesized that patients with sickle cell disease and severe hemolysis (Lactate Dehydrogenase level \> 484 IU/L) could have an increased risk of hypercoagulable state and subsequent thromboembolic complications.
Inclusion: Aged 8 years or older; Under clinical follow-up for a diagnosis of sickle cell disease, specifically genotypes S/S, S/beta0, or S/C; Patient covered by a social security or equivalent health insurance plan; Collection of the non-opposition for adults; Information of the minor and collection of the non-opposition from both parents.
Exclusion: Patient who has undergone a transfusion or therapeutic phlebotomy within the 3 months prior to inclusion; Patient participating in another interventional research protocol that may interfere with the present protocol (at the investigator\'s discretion); Patient under guardianship, curatorship, or legal protection; Patient subject to a legal protection measure; Person admitted to a health or social care institution for purposes other than research.